U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Dublin, Dec. 20, 2016 -- Research and Markets has announced the addition of the "Gastric Cancer: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.
Pipeline therapies will look to fulfil many areas of high unmet need left by the lack of targeted therapies approved for the treatment of gastric cancer.
This report addresses the following questions:
- What impact will the PD-1/PD-L1 inhibitor class of drugs have on the gastric cancer market?
- How will pipeline immunotherapies be positioned in the gastric cancer treatment space?
- Which targeted therapies are expected to experience the greatest growth over the forecast period?
- How will Eli Lilly look to maintain Cyramza's first-to-market advantage?
- What are the key drivers of the rapidly expanding gastric cancer market?
Key Topics Covered:
FORECAST: GASTRIC CANCER
- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Avelumab
- BBI
- (napabucasin)
- Cyramza (ramucirumab)
- GS-57
- Herceptin (trastuzumab)
- Keytruda (pembrolizumab)
- Lynparza (olaparib)
- Nimotuzumab
- Opdivo (nivolumab)
- Perjeta (pertuzumab)
- Primary Research Methodology
TREATMENT: GASTRIC CANCER
- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
EPIDEMIOLOGY: GASTRIC CANCER IN THE US, JAPAN, AND 5EU
- Executive Summary
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
MARKETED DRUGS: GASTRIC CANCER
- Executive Summary
- Product Overview
- Product profile: Cyramza
- Product profile: Herceptin
PIPELINE: GASTRIC CANCER
- Executive Summary
- Clinical Pipeline Overview
- Product profile (late stage): BBI6
- Product profile (late stage): GS-57
- Product profile (late stage): Keytruda
- Product profile (late stage): Lynparza
- Product profile (late stage): Opdivo
- Product profile (late stage): Perjeta
- Product profile (late stage): avelumab
- Product profile (late stage): nimotuzumab
For more information about this report visit http://www.researchandmarkets.com/research/m6cxm5/gastric_cancer
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs
